Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DB 1310

Next Previous
X
Search
Drug Profile

DB 1310

Alternative Names: DB-1310

Latest Information Update: 09 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duality Biologics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action DNA topoisomerase I inhibitors; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 14 Apr 2023 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 07 Apr 2023 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05785741) (Duality Biologics pipeline, April 2023)
  • 27 Mar 2023 DualityBio plans a phase I/IIa trial for Solid tumours (Late-staged disease, Metastatic diseases, Recurrent, Second-line therapy) in the US and China (NCT05785741)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top